STOCK TITAN

Protagonist Therapeutics (PTGX) Net Income by Year

PTGX NASDAQ

Protagonist Therapeutics, Inc reported a net loss of $130.1M in fiscal year 2025. This represents a decrease of 147.3% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to $82.9M in net income. The table below carries 12 fiscal years, from 2014 to 2025, and the quarters Protagonist Therapeutics, Inc has filed alongside them.

FY2025 annual
Net Income -$130.1M
YoY -147.3%
5Y CAGR n/m
10Y CAGR n/m
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

PTGX Net Income by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1610-KFY1510-KFY1410-K
Net Income$82.9M-$130.1M-147.3%$275.2Mn/m-$79.0Mn/m-$127.4Mn/m-$125.6Mn/m-$66.2Mn/m-$77.2Mn/m-$38.9Mn/m-$37.0Mn/m-$37.2Mn/m-$14.9Mn/m-$11.1M

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

PTGX Net Income by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
Net Income$162.8Mn/m$3.8Mn/m-$44.4M-133.7%-$39.3Mn/m-$34.8Mn/m-$11.7M-105.6%$131.7M-$33.2Mn/m-$30.6Mn/m$207.3Mn/mN/A-$34.1Mn/m

What net income means

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.

More Protagonist Therapeutics, Inc financials

Frequently Asked Questions

What was Protagonist Therapeutics, Inc's net income in fiscal year 2025?

Protagonist Therapeutics, Inc reported a net loss of $130.1M in fiscal year 2025.

How fast is Protagonist Therapeutics, Inc's net income growing?

Protagonist Therapeutics, Inc (PTGX) net income fell by 147.3% year over year, from $275.2M to -$130.1M in fiscal year 2025.

What is Protagonist Therapeutics, Inc's net income over the last twelve months?

Protagonist Therapeutics, Inc (PTGX) reported $82.9M in net income over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

Across the 12 fiscal years this page covers, Protagonist Therapeutics, Inc (PTGX) net income went from -$11.1M in fiscal year 2014 to -$130.1M in fiscal year 2025.

Protagonist Therapeutics, Inc (PTGX) reported $162.8M in net income in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Protagonist Therapeutics, Inc (PTGX) reported on that line in every period on record.